Management attributes consistent 2% to 3% core FFO per share growth to a repeatable strategy focused on high-credit government-adjacent tenancy and disciplined capital allocation.

The portfolio maintains high durability because assets are purpose-built for mission-critical functions like law enforcement and public health, which remain essential regardless of political or economic cycles.

Strategic diversification into state-level partnerships, such as the recent Virginia acquisition, is driven by credit quality comparable to federal tenants and the benefit of contractual rent escalations.

Management views the private sector's role as essential for modernizing government infrastructure, allowing agencies to focus on mission execution rather than the complexities of real estate ownership.

Operational performance remains strong with occupancy at 97% and weighted average lease terms of approximately 10 years, reinforcing the stability of the tenant base.

The company is actively transitioning toward a more conventional leverage profile with a medium-term target of approximately 6.0x to lower funding costs and improve investment-grade positioning.

Full-year 2026 core FFO guidance of $3.05 to $3.12 assumes approximately 3% growth, supported by the FDA Atlanta delivery and successful lease renewals.

Guidance methodology incorporates $50 million to $100 million in gross development-related investment and $50 million in wholly owned acquisitions for 2026.

Management expects cash leverage to trend below 7.5x as remaining lump-sum reimbursements from the FDA Atlanta project are received in the coming months.

The acquisition strategy targets a pipeline of approximately $1 billion, focusing on assets that provide a return spread of at least 100 basis points over the weighted average cost of capital.

Future growth is predicated on shifting focus toward 2027 renewals, with management noting that most 2026 renewals are already completed.

Completed a $44.5 million acquisition of a three-asset Virginia portfolio at an 11% cash cap rate, driven by a motivated seller and the company's ability to execute an all-cash bid.

The FDA Atlanta facility was formally delivered in December 2025, with $138.1 million in reimbursements received by year-end and an additional $15.6 million expected in early 2026.

Three major development projects in Florida, Arizona, and Oregon totaling 200,000 square feet are progressing toward deliveries in 2026 and 2027.

Management addressed federal budget volatility and 'DOGE' initiatives, characterizing them as potential tailwinds that favor efficient public-private partnerships over government ownership.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management expressed optimism for 2026, noting that current market conditions favor reliable buyers with strong balance sheets.

The team is prioritizing assets that offer significant spreads to their cost of capital rather than speculating on early-year volume.

Management welcomed the appointment of Ed Forst, citing his private sector expertise as a positive for future public-private partnerships.

They anticipate the government will increasingly look toward private capital to drive real estate efficiency and modernization.

Management clarified that while there is a 2027 expiration, it involves only 2,000 square feet and is immaterial to the portfolio.

The primary state tenants occupy over 50% of the assets with long-dated leases extending to 2034 and 2036.

Management argued that budget cuts typically target waste and fraud rather than the mission-critical functions housed in Easterly's buildings.

They emphasized that as agencies seek to cut deficits and improve efficiency, the demand for high-quality, well-maintained private sector facilities increases.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.